RCT | Zavegepant 10 mg nasal spray vs. placebo for the acute treatment of migraine
31 Mar, 2023 | 13:24h | UTCSafety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial – The Lancet Neurology (link to abstract – $ for full-text)